About Eikonoklastes
Eikonoklastes is a company based in Columbus (United States) founded in 2019 by Zhiwei Hu and Samuel Lee.. Eikonoklastes has raised $20.76 million across 5 funding rounds from investors including Elk Capital Partners, CincyTech and JobsOhio. The company has 3 employees as of December 31, 2021. Eikonoklastes offers products and services including ET-101 and SynCav1. Eikonoklastes operates in a competitive market with competitors including Daré Bioscience, Olema Oncology, Emergent BioSolutions, Atossa Therapeutics and Adjuvance Technologies, among others.
- Headquarter Columbus, United States
- Employees 3 as on 31 Dec, 2021
- Founders Zhiwei Hu, Samuel Lee
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$20.76 M (USD)
in 5 rounds
-
Latest Funding Round
$13.56 M (USD), Series B
Jul 17, 2025
-
Investors
Elk Capital Partners
& 3 more
-
Employee Count
3
as on Dec 31, 2021
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Eikonoklastes
Eikonoklastes offers a comprehensive portfolio of products and services, including ET-101 and SynCav1. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Overexpresses Caveolin-1 to protect neurons in neurodegenerative diseases.
Delivers gene copies for neuroprotection in ALS and similar conditions.
Unlock access to complete
Unlock access to complete
Leadership Team
7 people
Scientific Team
5 people
Board Team
1 people
Inventor Team
1 people
Unlock access to complete
Funding Insights of Eikonoklastes
Eikonoklastes has successfully raised a total of $20.76M across 5 strategic funding rounds. The most recent funding activity was a Series B round of $13.56 million completed in July 2025. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 5
- Last Round Series B — $13.6M
- First Round First Round
- Investors Count 4
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2025 | Amount | Series B - Eikonoklastes | Valuation |
investors |
|
| Jun, 2024 | Amount | Series B - Eikonoklastes | Valuation |
investors |
|
| Nov, 2023 | Amount | Series A - Eikonoklastes | Valuation |
investors |
|
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Eikonoklastes
Eikonoklastes has secured backing from 4 investors, including venture fund and institutional investors. Prominent investors backing the company include Elk Capital Partners, CincyTech and JobsOhio. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
CincyTech is engaged in venture capital investments for innovative startups.
|
Founded Year | Domain | Location | |
|
Startup Studio building companies in the US & Europe and Angel Network for Ohio based companies
|
Founded Year | Domain | Location | |
|
Provider of capital partners is a fundless sponsor
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Eikonoklastes
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Eikonoklastes
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Eikonoklastes Comparisons
Competitors of Eikonoklastes
Eikonoklastes operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Daré Bioscience, Olema Oncology, Emergent BioSolutions, Atossa Therapeutics and Adjuvance Technologies, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Non-hormonal pharmaceutical products for female contraceptives are developed.
|
|
| domain | founded_year | HQ Location |
Drug therapeutics for breast cancer treatment are developed.
|
|
| domain | founded_year | HQ Location |
Vaccines for viral infections are developed by the company.
|
|
| domain | founded_year | HQ Location |
Drugs for breast cancer treatment and prevention are developed.
|
|
| domain | founded_year | HQ Location |
Vaccine adjuvants are designed and manufactured for medical applications.
|
|
| domain | founded_year | HQ Location |
Tyrosine kinase inhibitors for breast cancer are developed.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Eikonoklastes
Frequently Asked Questions about Eikonoklastes
When was Eikonoklastes founded?
Eikonoklastes was founded in 2019 and raised its 1st funding round 2 years after it was founded.
Where is Eikonoklastes located?
Eikonoklastes is headquartered in Columbus, United States. It is registered at Columbus, Ohio, United States.
Who is the current CEO of Eikonoklastes?
Bruce M Halpryn is the current CEO of Eikonoklastes.
Is Eikonoklastes a funded company?
Eikonoklastes is a funded company, having raised a total of $20.76M across 5 funding rounds to date. The company's 1st funding round was a Series A of $2M, raised on Jun 28, 2021.
How many employees does Eikonoklastes have?
As of Dec 31, 2021, the latest employee count at Eikonoklastes is 3.
What does Eikonoklastes do?
Developer of tissue factor targeting therapeutics to treat cancer. The company is developing tissue factor targeting therapies that target cell surface receptors for cancers, endometriosis, and other diseases. The company has developed an L-ICON3 platform to create immune therapies engineered with a ligand conjugated to an IgG3 Fc to enable it to bind to cancer cells and treat triple-negative breast cancer. The cells activate complement activation (CDC) and antibody-dependent cellular cytotoxicity (ADCC) to kill cancer cells.
Who are the top competitors of Eikonoklastes?
Eikonoklastes's top competitors include Atossa Therapeutics, Daré Bioscience and Puma Biotechnology.
What products or services does Eikonoklastes offer?
Eikonoklastes offers ET-101 and SynCav1.
Who are Eikonoklastes's investors?
Eikonoklastes has 4 investors. Key investors include Elk Capital Partners, CincyTech, JobsOhio, and Rev1 Ventures.